ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control

Parkinsonism and Related Disorders

Volumn 13, Issue 4, 2007, Pages 214-218

  Koziorowski, Dariusz ^a   Friedman, Andrzej ^a   Arosio, Paolo ^b   Santambrogio, Paolo ^b   Dziewulska, Dorota ^a,c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Ferritin structure; Incidental Lewy body; Parkinson's disease

Indexed keywords

FERRITIN;

ARTICLE; BRAIN LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LEWY BODY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SUBSTANTIA NIGRA;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERRITINS; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; POSTMORTEM CHANGES; PROPORTIONAL HAZARDS MODELS; SUBSTANTIA NIGRA;

EID: 34247151294     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.10.002     Document Type: Article

References (39)

1. Forno L.S., and Langston J.W. Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration 2 (1993) 19-24
2. Smith T.A., and Prayson R.A. Lewy body disease. South Med J 89 (1996) 1174-1180
3. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
4. Dexter D.T., Sian J., Rose S., Hindmarsh J.S., Mann V.M., Cooper J.M., et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35 (1994) 38-44
5. Schapira A.H.V., Mann V.M., Cooper J.M., Dexter D.T., Daniel S.E., Jenner P., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142-2145
6. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction. Ann Neurol 32 (1992) 10-15
7. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
8. Griffiths P.D., Dobson B.R., Jones G.R., and Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 (1999) 667-673
9. Harrison P.M., and Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275 (1996) 161-203
10. Chasteen N.D., and Harrison P.M. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol 126 (1999) 182-194
11. Kwak E.L., Larochelle D.A., Beaumont C., Torti S.V., and Torti F.M. Role for NF-κB in regulation of ferritin H by Tumor Necrosis Factor alpha. J Biol Chem 270 (1995) 15285-15293
12. Connor J.R., Boeshore K.L., Benkovic S.A., and Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37 (1994) 461-465
13. Hallgren B., and Sourander P. The effect of age on the non-haemin iron the human brain. J Neurochem 3 (1958) 41-51
14. Gała{ogonek}zka-Friedman J., and Friedman A. Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol Exp 57 (1997) 217-225
15. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55 (1990) 16-20
16. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36 (1994) 876-881
17. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., and LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 65 (1995) 717-724
18. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
19. Luzzago A., Arosio P., Iacobello C., Ruggeri G., Capucci L., Brocchi E., et al. Immunochemical characterization of human liver and heart ferritins with monoclonal antibodies. Biochim Biophys Acta 872 (1986) 61-71
20. Arosio P., Cozzi A., Levi S., Luzzago A., Ruggeri G., Iacobello C., et al. A mutantional analysis of the epitops of recombinant human H-ferritin, Biochim. Biophys Acta 1039 (1990) 197-203
21. Thorpe S.J., Walker D., Arosio P., Heath A., Cook J., and Worwood M. International collaborative study to evaluate a recombinant L ferritin preparation as an International Standard. Clin Chem 43 (1997) 1582-1587
22. Winer B.J. Statistical Principal in Experimental Design (1962), McGraw-Hill, San Francisco
23. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., and Nowik I. Iron in parkinsonian and control substantia nigra-A Mössbauer spectroscopy study. Mov Disord 11 (1996) 8-16
24. Eggleton R.A., and Fitzpatrick R.W. New data and a revised structural model for ferrihydrite. Clays Clay Minerals 36 (1988) 111-114
25. Galazka-Friedman J., Bauminger E.R., Koziorowski D., and Friedman A. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. Biochim Biophys Acta 1688 (2004) 130-136
26. Götz M.E., Künig G., Riederer P., and Youdim M.B.H. Oxidative stress. Free radical production in neural degeneration. Pharmacol Ther 63 (1994) 37-122
27. McGeer P.L., and McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Related Disord 10 (2004) 3-7
28. Reif D.W., and Simmons R.D. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283 (1990) 537-541
29. Yoshida T., Tanaka M., Sotomatsu A., and Hirai S. Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci Lett 190 (1995) 21-24
30. Saporito M.S., Heikkila R.E., Youngster S.K., Nicklas W.J., and Geller H.M. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured mesencephalon: relationship to dopamine uptake affinity and inhibition of mitochondrial respiration. J Pharmacol Exp Ther 260 (1992) 1400-1409
31. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999) 717-721
32. Kwak E.L., Larochelle D.A., Beaumont C., Torti S.V., and Torti F.M. Role for NF-kappaB in regulation of ferritin H by Tumor Necrosis Factor alpha. J Biol Chem 270 (1995) 15285-15293
33. Torti F.M., and Torti S.V. Regulation of ferritin genes and protein. Blood 99 (2002) 3505-3516
34. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., and Hirsch E.C. Lack of upregulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 83 (2002) 320-330
35. Mulero V., and Brock J.H. Regulation of iron metabolism in murine J774 macrophages: role of nitric oxide-dependent and independent pathways following activation with gamma interferon and lipopolysaccharide. Blood 94 (1999) 2383-2389
36. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., and Youdim M.B.H. Brain iron and ferritin in Parkinson's and Alzheimer's disease. J Neurol Transm [P-D Sect] 2 (1990) 327-340
37. Zecca L., Gallorini M., Schuenemann V., Trautwein A.X., Gerlach M., Riederer P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76 (2001) 1766-1773
38. Fukae J., Takanashi M., Kubo S., Nishioka K., Nakabeppu K., Mori H., et al. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol 109 (2005) 256-262
39. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R., and Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64 (2005) 816-830